![]() |
市場調查報告書
商品編碼
2149237
免疫療法藥物市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026-2034年預測Immunotherapy Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
全球免疫療法市場在2025年達到3,439.8億美元,預計從2026年的3,943.6億美元成長至2034年的1.22兆美元,預測期內年複合成長率(CAGR)為15.16%。北美地區在2025年佔據全球市場主導地位,市場佔有率達47.54%,這主要得益於該地區高昂的醫療保健支出、活躍的臨床試驗活動、先進的腫瘤學研究以及不斷增加的已通過核准免疫療法產品。
免疫療法藥物目的是刺激、增強或恢復免疫系統識別和摧毀病原細胞的能力。由於癌症發病率上升、腫瘤學研究取得進展、新療法獲得監管部門批准的增加以及醫療保健支出的成長,該市場不斷擴大。製藥和生物製藥公司也在不斷開發將免疫療法與標靶治療結合的聯合治療。
市場定義和範圍
免疫療法藥物市場包括單株抗體、CAR-T細胞療法、癌症疫苗以及其他用於腫瘤、自體免疫疾病、感染疾病和其他適應症的免疫療法。該市場還涵蓋靜脈注射等通路,以及醫院藥房、零售藥房和藥房以及線上藥房。
市場動態
促進因素 - 細胞療法快速成長:CAR-T療法的推廣和新型異體「即用型」平台的出現推動市場成長。骨髓惡性腫瘤臨床療效的不斷提高、對細胞療法生產和基因編輯技術的投資,以及有利的監管環境,都在增強這一領域的實力。2025年6月,Allogene Therapeutics公司公佈了其CD70標靶產品的I期臨床試驗的正面結果。
限制因素 - 高昂的治療費用:先進免疫療法的高昂費用限制了患者的獲得,尤其是在中低收入國家。高昂的藥物研發成本、嚴格的監管要求以及不完善的償付機制進一步限制了市場擴張。
機會 - 免疫療法與標靶治療的聯合應用:聯合治療透過提高治療反應率和克服抗藥性機制,為血液腫瘤和固體癌帶來了巨大的機會。一線治療方案的核准也擴大了潛在患者群。
挑戰 - 安全隱患:嚴重的免疫相關不利事件,例如細胞激素釋放症候群、神經毒性、自體免疫反應、心肌炎和嚴重結腸炎,仍是重大挑戰。安全隱患也會使臨床開發和法規核准變得複雜。
趨勢 - 固體癌藥物核准數量增加:用於治療固體癌的查核點抑制劑、雙特異性抗體和細胞免疫療法的核准數量日益增加,擴大了目標市場。治療策略正轉向肺癌、乳癌、胃腸道癌症、子宮頸癌和惡性黑色素瘤等癌症的早期治療。
The global immunotherapy drugs market size was valued at USD 343.98 billion in 2025 and is projected to grow from USD 394.36 billion in 2026 to USD 1,220.02 billion by 2034, exhibiting a CAGR of 15.16% during the forecast period. North America dominated the global market with a 47.54% share in 2025, supported by high healthcare spending, extensive clinical trial activity, advanced oncology research, and a growing number of approved immunotherapy products.
Immunotherapy drugs are medications designed to stimulate, enhance, or restore the immune system's ability to recognize and destroy disease-causing cells. The market is expanding due to the rising incidence of cancer, advances in oncology research, increasing regulatory approvals for novel therapies, and growing healthcare expenditure. Pharmaceutical and biopharmaceutical companies are also increasingly developing combination regimens that pair immunotherapies with targeted therapies.
Market Definition and Scope
The immunotherapy drugs market includes therapies such as monoclonal antibodies, CAR-T cell therapies, cancer vaccines, and other immune-based treatments used across oncology, autoimmune diseases, infectious diseases, and other indications. The market also covers intravenous and subcutaneous administration routes and distribution through hospital pharmacies, retail pharmacies and drug stores, and online pharmacies.
Market Dynamics
Driver - Rapid Growth in Cell Therapies: The expansion of CAR-T therapies and emerging allogeneic "off-the-shelf" platforms is supporting market growth. Increasing clinical success in hematological malignancies, investments in cell-therapy manufacturing, gene-editing technologies, and supportive regulatory pathways are strengthening the segment. In June 2025, Allogene Therapeutics reported positive Phase 1 results for its CD70-targeting products.
Restraint - High Treatment Costs: High costs associated with advanced immunotherapies restrict patient access, particularly in low- and middle-income countries. Expensive drug development, strict regulatory requirements, and inadequate reimbursement practices further limit market expansion.
Opportunity - Immunotherapy-Targeted Therapy Combinations: Combination therapies are creating significant opportunities by improving treatment responses and addressing resistance mechanisms across hematologic and solid cancers. Increasing approvals in first-line settings are also expanding the potential patient population.
Challenge - Safety Concerns: Severe immune-related adverse events, including cytokine release syndrome, neurotoxicity, autoimmune reactions, myocarditis, and severe colitis, remain important challenges. Safety concerns can also complicate clinical development and regulatory review.
Trend - Increasing Approvals for Solid Tumors: Growing approvals of checkpoint inhibitors, bispecific antibodies, and cell-based immunotherapies for solid tumors are expanding the addressable market. Therapies are increasingly moving into earlier treatment lines for cancers such as lung, breast, gastrointestinal, cervical, and melanoma.
By Type: Monoclonal antibodies held the largest market share in 2025 due to increasing investment, expanding clinical pipelines, product launches, and regulatory approvals. CAR-T cell therapies are projected to be the fastest-growing segment, with a 34.08% CAGR.
By Indication: Oncology dominated the market in 2025 and is anticipated to account for 87.2% in 2026, driven by the global cancer burden and strong clinical adoption. Autoimmune diseases are projected to grow at a 13.02% CAGR.
By Route of Administration: Intravenous administration led the market and is expected to hold an 85.4% share in 2026, while subcutaneous administration is projected to grow at a 19.54% CAGR.
By Distribution Channel: Hospital pharmacies dominated and are expected to maintain an 80.1% share in 2026, while online pharmacies are projected to grow at a 21.10% CAGR.
North America: The region generated USD 163.52 billion in 2025 and remained the leading market. The U.S. market is projected to reach USD 171.04 billion in 2026, supported by healthcare investment, clinical research, and product approvals.
Europe: Europe is projected to reach USD 89.10 billion in 2026, recording a 14.46% growth rate. The U.K., Germany, and France are expected to generate USD 18.24 billion, USD 19.92 billion, and USD 14.32 billion, respectively.
Asia Pacific: The regional market is projected to reach USD 71.30 billion in 2026, supported by rising cancer incidence, clinical development, and improved access to innovative therapies. China and India are projected to reach USD 21.43 billion and USD 12.69 billion.
Latin America and Middle East & Africa: Latin America is expected to reach USD 26.57 billion in 2026, while the GCC market is projected to reach USD 7.42 billion, supported by increasing clinical research and commercial access.
Competitive Landscape
The market has a semi-consolidated competitive structure. Major players include Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, AstraZeneca, Pfizer Inc., Novartis AG, Gilead Sciences, Inc., Johnson & Johnson, Amgen Inc., and Regeneron Pharmaceuticals, Inc. Companies are strengthening their positions through clinical innovation, collaborations, biologics manufacturing, product development, and strategic investments.
Report Coverage
The report provides comprehensive analysis of market size and forecast for 2025, 2026, and 2034, along with market dynamics, trends, segmentation, regional insights, technological advancements, pipeline analysis, product development, strategic initiatives, competitive landscape, and key industry developments.
Conclusion
The global immunotherapy drugs market is projected to expand from USD 343.98 billion in 2025 to USD 394.36 billion in 2026 and USD 1,220.02 billion by 2034. Rising cancer incidence, advances in cell therapies, increasing regulatory approvals, and growing adoption of immunotherapy-targeted combinations will continue to support market expansion. At the same time, high treatment costs and safety concerns remain important considerations. Continued innovation in monoclonal antibodies, CAR-T therapies, solid-tumor applications, and subcutaneous formulations is expected to shape the market's future development.
Global Immunotherapy Drugs Market Scope
By Type
By Indication
By Route of Administration
By Distribution Channel
By Region